Mesoblast Reports Fiscal Year Financial Results and Revenue Miss

Mesoblast Limited (MESO) has released its fiscal year financial results, reporting a revenue of $115 million. This figure represents a significant miss against market expectations, falling short by approximately $44 million. The company reported a gross profit on total sales when excluding amortization expenses of $115 million. Despite the revenue shortfall, the company continues to focus on its product pipeline, including Ryoncil and Rexlemestrocel-L, as it navigates regulatory milestones and clinical developments.

By https://seekingalpha.com/user/65109143/bio · Seeking Alpha ·

Mesoblast Reports Fiscal Year Financial Results and Revenue Miss

Tickers: $MESO

Topics: earnings report financial results revenue miss

Read the full article at Seeking Alpha

More World news